

May 13, 2019

Yusuf Ali, Ph.D., CEO of RIBOMIC USA Inc., talks on SUSHI study at TIDES meeting

We are conducting phase I/IIa trial using RBM-007 (anti-FGF2 aptamer) for the treatment of exudative age-related macular degeneration (AMD) in the United States (SUSHI study). All 9 patients have been enrolled and treated with RBM-007. No serious adverse events have occurred so far in the entire trial.

At the TIDES meeting to be held from May 20 to 23 in San Diego, Yusuf Ali, Ph.D., CEO of RIBOMIC USA Inc., will discuss the characteristics of RBM-007 as a new drug, current status of the SUSHI study, and the plan for next Phase II trial.

Presentation date: May 23, 2019

Presenter: Yusuf Ali, Ph.D. (CEO, RIBOMIC USA Inc.)

Presentation title: Anti-FGF2 aptamer RBM-007 in phase I/IIa trials for wet AMD